



NCI SBIR AND YOUR STATE:

NEW YORK



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$50.9 million** in funding across **38 Phase II SBIR/STTR grants** to small businesses in New York. The following economic impact estimates quantify the program's contributions to the state's economy:



\$242.1M

IN TOTAL DIRECT SALES



\$1.1B

IN TOTAL ECONOMIC IMPACT



4.2K

JOBS CREATED



\$52.4M

IN STATE & LOCAL TAXES COLLECTED



17

COMPANIES WITH SALES

**These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in New York: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$152.1M in funding across all grants to oncology-focused small businesses in the state.*

Success stories include:

KONING CORPORATION

Koning Corporation used SBIR funding to develop the Koning Breast CT system for scanning 3D images that improve tumor detection in breast tissue and remove compression to increase patient comfort. Originally licensed from the University of Rochester, the technology has FDA approval in the US, CE Mark in Europe, and regulatory approvals in five other countries.

LUCID, INC.

Lucid's SBIR-funded VivaScope® confocal imager provides in vivo cellular resolution images of skin to reduce the need for invasive skin biopsies and improve the efficiency for diagnosis and treatment of melanoma and skin conditions. The company achieved FDA approval in the US, CE Mark in Europe, and regulatory approvals in three other countries.

The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to ncisbir@mail.nih.gov.